AnaptysBio Dirección

Dirección controles de criterios 3/4

El CEO de AnaptysBio es Dan Faga , nombrado en Mar 2022, tiene una permanencia de 2.67 años. compensación anual total es $7.46M, compuesta por 8.6% salario y 91.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.32% de las acciones de la empresa, por valor de $9.68M. La antigüedad media del equipo directivo y de la junta directiva es de 2.7 años y 3.7 años, respectivamente.

Información clave

Dan Faga

Chief Executive Officer (CEO)

US$7.5m

Compensación total

Porcentaje del salario del CEO	8.6%
Permanencia del CEO	2.7yrs
Participación del CEO	1.3%
Permanencia media de la dirección	2.7yrs
Promedio de permanencia en la Junta Directiva	3.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dan Faga en comparación con los beneficios de AnaptysBio?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$166m
Jun 30 2024	n/a	n/a	-US$170m
Mar 31 2024	n/a	n/a	-US$163m
Dec 31 2023	US$7m	US$641k	-US$164m
Sep 30 2023	n/a	n/a	-US$148m
Jun 30 2023	n/a	n/a	-US$144m
Mar 31 2023	n/a	n/a	-US$137m
Dec 31 2022	US$25m	US$474k	-US$129m
Sep 30 2022	n/a	n/a	-US$135m
Jun 30 2022	n/a	n/a	-US$108m
Mar 31 2022	n/a	n/a	-US$76m
Dec 31 2021	US$310k	n/a	-US$58m

Compensación vs. Mercado: La compensación total de Dan($USD7.46M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD1.45M).

Compensación vs. Ingresos: La compensación de Dan ha sido consistente con los resultados de la empresa en el último año.

CEO

Dan Faga (44 yo)

2.7yrs

Permanencia

US$7,461,920

Compensación

Mr. Daniel R. Faga, also known as Dan, is Director of Affini-T Therapeutics, Inc. from April 2022. He serves as Director at AnaptysBio, Inc. since November 2021 and is its President and Chief Executive Off...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Daniel Faga	President	2.7yrs	US$7.46m	1.32% $ 9.7m
Eric Loumeau	Chief Legal Officer	6.3yrs	US$2.26m	0.011% $ 78.1k
Paul Lizzul	Chief Medical Officer	4.3yrs	US$2.44m	0.051% $ 371.1k
Dennis Mulroy	Chief Financial Officer	4.3yrs	US$1.81m	0.016% $ 114.3k
Beth Mueller	Senior Vice President of Human Resources	5.1yrs	sin datos	sin datos
Martin Dahl	Senior Vice President of Research	2.8yrs	sin datos	sin datos
Benjamin Stone	Chief Business Officer	less than a year	sin datos	sin datos
Douglas Rich	Senior Vice President of CMC	1.8yrs	sin datos	sin datos
Monique Da Silva	Senior Vice President of Corporate Affairs	less than a year	sin datos	sin datos
Priya Raina	Senior Vice President of Clinical Operations	less than a year	sin datos	sin datos
Min Bao	Senior Vice President of Clinical Development	less than a year	sin datos	sin datos

2.7yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0HFQ se considera experimentado (2.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Daniel Faga	President	3yrs	US$7.46m	1.32% $ 9.7m
John Orwin	Independent Chairman of the Board	1.2yrs	US$338.08k	0.011% $ 80.4k
Hollings Renton	Lead Independent Director	9.4yrs	US$342.38k	0.0064% $ 47.0k
John Schmid	Independent Director	9.4yrs	US$335.38k	0.013% $ 94.0k
Dennis Fenton	Independent Director	6.7yrs	US$331.88k	0.0064% $ 47.0k
Magda Marquet	Independent Director	3.8yrs	US$318.38k	0.013% $ 94.0k
Oleg Nodelman	Independent Director	3.6yrs	sin datos	sin datos
J. Ware	Independent Director	7.3yrs	US$338.38k	0.025% $ 180.8k
Rita Jain	Independent Director	1.6yrs	US$495.60k	0.015% $ 109.3k
Dolca Thomas	Member of Scientific Advisory Board	1.8yrs	sin datos	sin datos
Luisa Salter-Cid	Member of Scientific Advisory Board	no data	sin datos	sin datos
John Monroe	Member of Scientific Advisory Board	no data	sin datos	sin datos

3.7yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de 0HFQ se considera experimentada (3.7 años de antigüedad promedio).

AnaptysBio Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

AnaptysBio, Inc., Annual General Meeting, Jun 12, 2024

President recently sold US$3.4m worth of stock

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Recent updates

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2024 earnings released: US$1.14 loss per share (vs US$1.41 loss in 3Q 2023)

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100.393177 million.

Second quarter 2024 earnings released: US$1.71 loss per share (vs US$1.50 loss in 2Q 2023)

New minor risk - Shareholder dilution

Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

First quarter 2024 earnings released: US$1.64 loss per share (vs US$1.58 loss in 1Q 2023)

AnaptysBio, Inc., Annual General Meeting, Jun 12, 2024

President recently sold US$3.4m worth of stock

Full year 2023 earnings released: US$6.08 loss per share (vs US$4.57 loss in FY 2022)

No longer forecast to breakeven

No longer forecast to breakeven

High number of new directors

High number of new directors

No longer forecast to breakeven

New minor risk - Profitability

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$1.18 loss in 3Q 2022)

AnaptysBio, Inc. Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

High number of new directors

High number of new directors

AnaptysBio, Inc. Announces Board Changes

High number of new directors

High number of new directors

Second quarter 2023 earnings released: US$1.50 loss per share (vs US$1.15 loss in 2Q 2022)

AnaptysBio, Inc. and GSK-Partner Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approved in U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

Forecast to breakeven in 2025

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$1.58 loss per share (vs US$1.31 loss in 1Q 2022)

Forecast to breakeven in 2025

Forecast to breakeven in 2025

AnaptysBio, Inc. (NasdaqGS:ANAB) announces an Equity Buyback for $50 million worth of its shares.

AnaptysBio Announces Portfolio

Anaptysbio- and GSK-Partnered Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Meets Primary Endpoint in Phase 3 Ruby Trial in Primary Advanced or Recurrent Endometrial Cancer

Anaptysbio and Gsk-Partnered Immuno-Oncology Agents Jemperli (Dostarlimab-Gxly) and Cobolimab Show Positive Progress in Two Separate Non-Small Cell Lung Cancer Trials

AnaptysBio, Inc. Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa

First quarter 2022 earnings released: US$1.31 loss per share (vs US$0.66 loss in 1Q 2021)

AnaptysBio, Inc., Annual General Meeting, Jun 23, 2022

Forecast to breakeven in 2024

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

AnaptysBio, Inc. Announces FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

First quarter 2021 earnings released: US$0.66 loss per share (vs US$0.30 loss in 1Q 2020)

AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint

Full year 2020 earnings released: US$0.73 loss per share (vs US$3.60 loss in FY 2019)

Revenue beats expectations

AnaptysBio, Inc. Announces Board Changes

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad